Hung, C-H
, Chang, T-S, Huang, C-F, Kuo, H-T, Lo, C-C, Huang, C-W, Chong, L-W, Cheng, P-N, Yeh, M-L, Peng, C-Y, Cheng, C-Y, Huang, J-F, Bair, M-J, Lin, C-L, Yang, C-C, Wang, S-R, Hsieh, T-Y, Lee, T-H, Lee, P-L, Wu, W-C, Lin, C-L, Su, W-W, Yang, S, Wang, C-C, Hu, J-T, Mou, L-J, Chen, C-T, Huang, Y-H, Chang, C-C, Huang, J-S, Chen, G-Y, Gao, J-N, Tai, C-M, Liu, C-J, Lee, M-H
, Tsai, P-C, Dai, C-Y, Kao, J-H, Lin, H-C, Chuang, W-L, Chen, C, Tseng, K-C & Yu, M-L 2022, '
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naive patients with compensated cirrhosis: real-world experience from Taiwan HCV registry',
Journal of Hepatology, vol. 77.